Physician profile
Eric Kane
NPI 1770076168
$3,144.13
in general payments reported to CMS, 2019-2025
27 companies · $20.67 in 2025
The $20.67 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.50 · 2021: $456 · 2022: $1,768 · 2023: $842 · 2025: $20.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $336.87 | 2021-2023 | |
| Novo Nordisk INC | $297.18 | 2021-2023 | Rybelsus, Ozempic, Tresiba |
| Glaxosmithkline, LLC. | $265.58 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $260.73 | 2021-2023 | |
| Amgen INC. | $208.07 | 2021-2023 | Otezla, Repatha |
| Lilly USA, LLC | $202.65 | 2020-2023 | Mounjaro, Jardiance |
| Pfizer INC. | $191.23 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $166.28 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $158.38 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.74 | 2020-2023 | Xifaxan |
| Intuity Medical INC | $118.80 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Dexcom, INC. | $113.69 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $106.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $103.82 | 2022-2023 | |
| Esperion Therapeutics, INC. | $89.84 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $69.25 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.62 | 2021-2023 | Jardiance, Stiolto Respimat |
| Exact Sciences Corporation | $43.72 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $33.09 | 2021 | |
| Merck Sharp & Dohme LLC | $27.71 | 2021 | |
| Daiichi Sankyo INC. | $25.67 | 2023 | Injectafer |
| Mannkind Corporation | $21.28 | 2023 | Afrezza |
| Boston Scientific Corporation | $20.91 | 2022 | |
| Neurocrine Biosciences, INC. | $20.67 | 2025 | |
| Amarin Pharma, INC. | $19.82 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.98 | 2021 | |
| Seqirus USA INC | $17.51 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.